Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015 for the Appointment of Auditors
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts less than Nifty Microcap 250 and 10.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bajaj Healthcare reported FY2026 audited standalone results with revenue from operations growing 12.6% to Rs 61,103.14 lakhs from Rs 54,260.24 lakhs. However, profit after tax from continuing operations fell 50% to Rs 2,131.04 lakhs from Rs 4,292.88 lakhs due to a Rs 3,324.66 lakh exceptional item — income reversal from a technical know-how arrangement with a Middle East customer affected by regional instability. Total comprehensive income for the year was Rs 1,637.58 lakhs versus Rs 4,086.56 lakhs in the prior year. The Board recommended a final dividend of Rs 1.50 per share (30% on Rs 5 face value), subject to shareholder approval. The statutory auditor issued an unmodified (clean) opinion. The company also appointed M/s. JCR & Co. LLP as internal auditors for FY2026-27 and reappointed M/s. V.J. Talati & Co. as cost auditors.
Despite solid revenue growth, the large exceptional item severely impacted profitability, resulting in a 60% decline in total comprehensive income for the year. The clean audit opinion provides some comfort, but investors may react negatively to the profit decline unless the Middle East-related reversal is viewed as a one-time event.